The statements below are read from Goldline Pharmaceutical Ltd’s filed results, 1 filed quarter and 4 fiscal years on record, standalone basis. Price-linked ratios are computed at the last close, sector medians across the served universe, ownership from the shareholding pattern, and any cell whose input isn’t on record shows a dash, never an estimate.
Latest: H2 FY25-26 · filed Jun 10, 2026 · audited
This company files half-yearly statements with the exchange — each column is a six-month period; discrete quarterly figures are not published.
| ₹ Cr | H2 FY26Mar 2026Latest | YoYlatest |
|---|---|---|
| Sales | 17.3 | — |
| 13.0 | — | |
| Operating profit | 4.30 | — |
| OPM % | 24.9% | — |
| Other income | 0.00 | — |
| Interest | 0.65 | — |
| Depreciation | 0.12 | — |
| Profit before tax | 3.53 | — |
| Tax % | 21.9% | — |
| Net profit | 2.76 | — |
| EPS (₹) | 3.43 | — |
No results filing with a recorded time yet — reactions appear from the first quarter whose announcement we timestamped (May 2026 onward), on the session the market could trade it.
